Comment
doi: 10.1001/jamaoto.2020.4276.
Regarding Use of Topical Steroids in Patients With COVID-19-Associated Olfactory Loss-Reply
Affiliations
- PMID: 33211079
- PMCID: PMC8027905
- DOI: 10.1001/jamaoto.2020.4276
Item in Clipboard
Comment
Regarding Use of Topical Steroids in Patients With COVID-19-Associated Olfactory Loss-Reply
JAMA Otolaryngol Head Neck Surg.
.
No abstract available
Conflict of interest statement
Comment on
-
Regarding Use of Topical Steroids in Patients With COVID-19-Associated Olfactory Loss.JAMA Otolaryngol Head Neck Surg. 2021 Jan 1;147(1):110. doi: 10.1001/jamaoto.2020.4275. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33211102 No abstract available.
Similar articles
-
Regarding Use of Topical Steroids in Patients With COVID-19-Associated Olfactory Loss.JAMA Otolaryngol Head Neck Surg. 2021 Jan 1;147(1):110. doi: 10.1001/jamaoto.2020.4275. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33211102 No abstract available.
-
Systemic steroids may enhance recovery from loss of smell and taste in hospitalized coronavirus disease 2019 (COVID-19) patients: an observational study.Int Forum Allergy Rhinol. 2021 Dec;11(12):1689-1693. doi: 10.1002/alr.22848. Epub 2021 Jun 16. Int Forum Allergy Rhinol. 2021. PMID: 34132052 Free PMC article. No abstract available.
-
[Loss of smell, a preliminary indicator of COVID-19].Rev Med Inst Mex Seguro Soc. 2021 Feb 2;59(1):4-6. doi: 10.24875/RMIMSS.M21000046. Rev Med Inst Mex Seguro Soc. 2021. PMID: 33666408 Spanish.
-
Therapeutic use of steroids in non-chronic rhinosinusitis olfactory dysfunction: a systematic evidence-based review with recommendations.Int Forum Allergy Rhinol. 2019 Feb;9(2):165-176. doi: 10.1002/alr.22240. Epub 2018 Nov 24. Int Forum Allergy Rhinol. 2019. PMID: 30472771
-
Anosmia as a presenting symptom of SARS-CoV-2 infection in healthcare workers - A systematic review of the literature, case series, and recommendations for clinical assessment and management.Rhinology. 2020 Aug 1;58(4):394-399. doi: 10.4193/Rhin20.189. Rhinology. 2020. PMID: 32386285
Cited by
-
Treatment strategies for postviral olfactory dysfunction: A systematic review.Allergy Asthma Proc. 2022 Mar 1;43(2):96-105. doi: 10.2500/aap.2022.43.210107. Allergy Asthma Proc. 2022. PMID: 35317886 Free PMC article.
-
Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013877. doi: 10.1002/14651858.CD013877.pub3. Cochrane Database Syst Rev. 2022. PMID: 36063364 Free PMC article.
-
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.Cochrane Database Syst Rev. 2021 Jul 22;7(7):CD013876. doi: 10.1002/14651858.CD013876.pub2. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 Sep 5;9:CD013876. doi: 10.1002/14651858.CD013876.pub3. PMID: 34291813 Free PMC article. Updated.
-
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013876. doi: 10.1002/14651858.CD013876.pub3. Cochrane Database Syst Rev. 2022. PMID: 36062970 Free PMC article.
-
Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.Cochrane Database Syst Rev. 2021 Jul 22;7(7):CD013877. doi: 10.1002/14651858.CD013877.pub2. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 Sep 5;9:CD013877. doi: 10.1002/14651858.CD013877.pub3. PMID: 34291812 Free PMC article. Updated.
References
-
- Sher MR, Steven GC, Romett JL, et al. EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps. Rhinology. 2020;58(1):25–35. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
